Details of the Drug Pharmacogenomic Perturbation Atlas
General Information of Drug (ID: DMGN1PW)
| Drug Name | ||||||
|---|---|---|---|---|---|---|
| Synonyms |
Arifon; Bajaten; Cormil; Damide; Fludex; Idapamide; Indaflex; Indamol; Indapamida; Indapamidum; Ipamix; Lozide; Lozol; Metindamide; Natrilix; Natrix; Noranat; Pressurai; Tandix; Tertensif; Veroxil; RHC 2555; SE 1520; USV 2555; Apo-Indapamide; Indapamida [INN-Spanish]; Indapamide (USP); Indapamidum [INN-Latin]; Lozol (TN); Natrilix (TN); Natrix (TN); Novo-Indapamide; Nu-Indapamide; S-1520; SE-1520; Indapamide (JAN/USP); Indapamide [USAN:INN:BAN:JAN]; N-[4-Chloro-3-sulfamoylbenzamido]-2-methylindoline; NLozol, Arifon, Fludex, Noranat, Veroxil, Tertensif, Indapamide; N-(4-Chloro-3-sulfamoylbenzamido)-2-methylindoline; Benzamide, 3-(aminosulfonyl)-4-chloro-N-(2,3-dihydro-2-methyl-1H-indol-1-yl)-(9CI); 1-(4-Chloro-3-sulfamoylbenzamido)-2-methylindoline; 3-(Aminosulfonyl)-4-chloro-N-(2,3-dihydro-2-methyl-1H-indol-1-yl)benzamide; 4-Chloro-N-(2-methyl-1-indolinyl)-3-sulfamoylbenzamide; 4-chloro-N-(2-methyl-2,3-dihydroindol-1-yl)-3-sulfamoylbenzamide
| |||||
| Therapeutic Class | Antihypertensive Agents | |||||
| Cross-matching ID | ||||||
Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
|
|
||||||||||||||||
|
||||||||||||||||
Pharmacogenomic Perturbation Across Diseases and Tissues
|
Bone
Osteosarcoma
Breast
Breast adenocarcinoma
Breast epithelium
Normal
Cervix
Cervical adenocarcinoma
Colon
Colorectal adenocarcinoma
Kidney
Normal (Immortalized)
Normal (Transformed)
Liver
Hepatocellular carcinoma
Lung
Lung adenocarcinoma
Non-small cell lung carcinoma
Pancreas
Pancreatic carcinoma
Peripheral blood
Acute monocytic leukemia
T-cell acute lymphoblastic leukemia
Prostate
Prostate carcinoma
Skin
Melanoma
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
